28 de fevereiro de 2017 | 11h18
For sufferers of conditions such as epilepsy and multiple sclerosis, Brazils recognition of CBDs therapeutic benefits is an important step towards functional, fulfilling lives and Elixinol is proud to be able to be part of the therapy for treating these very serious conditions, said Paul Benhaim, CEO of Elixinol.
Although its relationship with cannabis remains complicated, Brazil joins countries like Japan, whose perceptions are shifting as they once again recognize the benefits of hemp.
Doctors in Brazil may prescribe CBD, including Elixinol, for treatment of intractable seizures. In 2014 Federal Medical Council of Brazil)(CFM) officially authorized the compassionate use of CBD for the treatment of intractable epilepsy in children and adolescents.
It is estimated that over 2 million Brazilians suffer from epileptic seizures and over 675,000 suffer from intractable seizures.
In 2015, ANVISA (National Agency of Sanitary Surveillance) defined the procedures for the importation of CBD products into Brazil by individuals, hospitals and health insurance companies, as published in the Resolução da Diretoria Colegiada (RDC) 17/2015.
In 2016, Elixinol hemp oil was included in ANVISAs list of most frequently imported products and will have a simpler authorization process, as stated in the health agencys RDC 128/2016.
Its an honor to be a working with the medical community, the people and the government of Brazil to bring high-quality, organic hemp relief to the sufferers whose doctors see CBD as a treatment option, said Dr. Philip Blair, MD, Elixinol Medical Advisor.
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol provides CBD products globally in the United States, Japan, Brazil, Puerto Rico and the UK. More information available at Elixinol.com.
Media Contact: Chris Husong Elixinol 408-420-8890 (m) chris@elixinol.com
Encontrou algum erro? Entre em contato
Os comentários são exclusivos para assinantes do Estadão.
